Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.68
-$0.075-2.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 79.89M | 100.62M | 117.59M | 137.18M | 150.28M |
| Total Receivables | 1.96M | 3.10M | 3.35M | 2.78M | 13.18M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 4.79M | 3.58M | 3.24M | 3.12M | 3.79M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 86.63M | 107.31M | 124.18M | 143.08M | 167.25M |
|
|
|||||
| Total Current Assets | 86.63M | 107.31M | 124.18M | 143.08M | 167.25M |
| Net Property, Plant & Equipment | 9.28M | 10.60M | 12.14M | 13.54M | 14.80M |
| Long-term Investments | 949.00K | 949.00K | 949.00K | 949.00K | 949.00K |
| Goodwill | 949.00K | 949.00K | 949.00K | 949.00K | 949.00K |
| Total Other Intangibles | 547.00K | 583.00K | 620.00K | 656.00K | 693.00K |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 1.09M | 1.09M | 1.10M | 993.00K | 997.00K |
| Total Assets | 98.50M | 120.53M | 138.98M | 159.22M | 184.69M |
|
|
|||||
| Total Accounts Payable | 276.00K | 1.09M | 1.42M | 611.00K | 1.96M |
| Total Accrued Expenses | 10.55M | 12.34M | 16.74M | 13.62M | 14.22M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 5.29M | 5.15M | 5.00M | 4.86M | 4.72M |
| Total Finance Division Other Current Liabilities | 34.08M | 67.20M | 96.06M | 123.77M | 123.63M |
| Total Other Current Liabilities | 34.08M | 67.20M | 96.06M | 123.77M | 123.63M |
| Total Current Liabilities | 50.20M | 85.77M | 119.23M | 142.86M | 144.54M |
|
|
|||||
| Total Current Liabilities | 50.20M | 85.77M | 119.23M | 142.86M | 144.54M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 2.86M | 4.24M | 5.60M | 6.89M | 8.15M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 20.39M | 30.98M | 37.61M | 40.70M | 63.68M |
| Total Liabilities | 73.45M | 120.99M | 162.43M | 190.45M | 216.37M |
|
|
|||||
| Common Stock & APIC | 693.10M | 691.10M | 686.96M | 684.97M | 677.99M |
| Retained Earnings | -668.05M | -691.58M | -710.46M | -716.19M | -709.66M |
| Treasury Stock & Other | -1.00K | 27.00K | 40.00K | -4.00K | -10.00K |
| Total Common Equity | 25.05M | -456.00K | -23.45M | -31.23M | -31.68M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 25.05M | -456.00K | -23.45M | -31.23M | -31.68M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 25.05M | -456.00K | -23.45M | -31.23M | -31.68M |
|
|
|||||